Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3978

Sort by

Sort Order Select

Journal Articles

Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma

Blood blood.2024027949.

https://doi.org/10.1182/blood.2024027949

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Blood (2025) 145 (23): 2762–2767.

https://doi.org/10.1182/blood.2024026831

Published: 2025

Includes: Supplemental data

Journal Articles

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Blood (2025) 145 (23): 2733–2745.

https://doi.org/10.1182/blood.2024025525

Published: 2025

Includes: Supplemental data

Journal Articles

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

Mark Dalgetty, Jorge Cortes

Blood (2025) 145 (23): 2701–2708.

https://doi.org/10.1182/blood.2024027944

Published: 2025

Journal Articles

STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL

Blood (2025) 145 (23): 2793–2798.

https://doi.org/10.1182/blood.2025028566

Published: 2025

Includes: Supplemental data

Journal Articles

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment

Viktoria Blumenberg, Benjamin R. Puliafito, Charlotte E. Graham, Mark B. Leick, Md. Raihan Chowdhury, Maxx King, Deshea L. Harris, Noopur S. Raje, Andrew R. Branagan, Andrew J. Yee, Diana Cirstea, Kathleen M. E. Gallagher, Jörg Dietrich, Marcela V. Maus, Matthew J. Frigault

Blood (2025) 145 (23): 2788–2793.

https://doi.org/10.1182/blood.2024028172

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies

Blood blood.2025028387.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

Nora M. Gibson, Eugene Khandros, Caitlin W. Elgarten, Elizabeth Worster, Dimitrios S. Monos, Alexis A. Thompson, Janet L. Kwiatkowski, Timothy S. Olson

Blood (2025) 145 (22): 2666–2670.

https://doi.org/10.1182/blood.2024027034

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial

Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, Katia Pini, Georg Stüssi, Gisela Müller, Nathan Cantoni, Richard Cathomas, Ulrich Mey, Anouk Widmer, Thorsten Zenz, Michael Gregor, Dominik Heim, Martin Andres, Rudolf Benz, Davide Rossi

Blood (2025) 145 (22): 2587–2598.

https://doi.org/10.1182/blood.2024026879

Published: 2025

Includes: Supplemental data

Journal Articles

Histo–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

Asbjørn L. Onsaker, Anna Y. Arntzen, David-Alexandre Trégouët, Therese H. Nøst, Weihong Tang, Weihua Guan, Christian Jonasson, Pierre-Emmanuel Morange, Kristian D. Hindberg, Aaron R. Folsom, Kristian Hveem, Vânia M. Morelli, John-Bjarne Hansen

Blood (2025) 145 (22): 2656–2665.

https://doi.org/10.1182/blood.2024025923

Published: 2025

Includes: Supplemental data

Journal Articles

Lymphoid malignancies in patients with Shwachman-Diamond syndrome

Helen D. Reed, Hyunwoo Do, Edie Weller, Marian H. Harris, Christopher R. Reilly, Harrison K. Tsai, Jason E. Farrar, Bonnie W. Lau, Lauren Pommert, Christopher Gamper, Ian Atkinson, Katherine Coyne, Margret Joos, Sara Loveless, Sarah Steltz, Leah Cheng, Maggie Malsch, Kasiani Myers, Akiko Shimamura

Blood (2025) 145 (21): 2528–2532.

https://doi.org/10.1182/blood.2024026507

Published: 2025

Journal Articles

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Blood (2025) 145 (21): 2447–2459.

https://doi.org/10.1182/blood.2024027500

Published: 2025

Includes: Supplemental data

Journal Articles

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

Blood (2025) 145 (21): 2518–2527.

https://doi.org/10.1182/blood.2024026915

Published: 2025

Includes: Supplemental data

Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Chad M. Williams, Joshua Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2025) 145 (20): 2303–2311.

https://doi.org/10.1182/blood.2024027347

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos

Blood (2025) 145 (20): 2353–2360.

https://doi.org/10.1182/blood.2024027686

Published: 2025

Journal Articles

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Zachariah DeFilipp, Haesook T. Kim, Laura W. Knight, Suzanne M. O’Connor, Shilton E. Dhaver, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Jooho Chung, Areej El-Jawahri, Matthew J. Frigault, Steven McAfee, Richard A. Newcomb, Paul V. O’Donnell, Thomas R. Spitzer, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2025) 145 (20): 2312–2316.

https://doi.org/10.1182/blood.2024028005

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

Blood blood.2024027902.

https://doi.org/10.1182/blood.2024027902

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jerome Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean Benoit Arlet, Jeremie Dion, Mael Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thepot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoit Faucher, Estibaliz Lazaro, Pr, Veronique Morel, Antoine Neel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cedric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean Baptiste Rieu, Olivier Fain, Sophie Anne Georgin-Lavialle, Pr, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène M Mékinian, Thibault Comont

Blood blood.2024028133.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Blood (2025) 145 (19): 2138–2148.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment

Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial

Histo–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

Lymphoid malignancies in patients with Shwachman-Diamond syndrome

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only